VP of Biology with extensive experience in preclinical small molecule drug development from analysis of HTS hits, through lead optimization to clinical candidate selection, support of CTA/IND filing and phase I/II clinical trials. Responsible for in vitro biology and in vivo pharmacology focused on inflammatory and rare diseases. Project leader of cross-functional teams involved in clinical candidate selection.Selection of oral RIP1 inhibitor IND candidate for inflammatory disease. CTA documents, biomarker studies. RIP1 program was partnered with Eli Lilly in February 2021 with upfront payment of $125 million and potential for up to $835 million in future milestones,

Director of the immunology team running all preclinical biology and pharmacology studies for immunology programs.Selection of oral IRAK1/4 inhibitor IND candidate for systemic inflammation, support of CTA filing.Partnering of oral JAK1/3 inhibitor for skin indications.

Director of the immunology team running all preclinical biology and pharmacology studies for immunology programs.Selection of second JAK1/3 inhibitor IND candidate for rheumatoid arthritis.Partnering of inhaled JAK1/3 inhibitor for asthma with AZ.

Project leader for the JAK1/3 kinase inhibitor program.Selection of IND candidate for transplant rejection and rheumatoid arthritis. IND documents, biomarker studies.Follow-on topical INDs (ski, eye).

Project leader for the JAK1/3 kinase inhibitor program.

Mechanism of action studies for high-content screening hits for oncology. Identification of Aurora kinase inhibitors led to Aurora kinase program and selection on IND candidate.

Syk kinase inhibitor project.IND reports for oral Syk inhibitor, now commercial product for ITP.Partnering of inhaled Syk inhibitor with Pfizer.